Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has entered into a partnership with US genomics giant Illumina (NSDQ: ILMN). The collaboration aims to advance the precise diagnosis of urinary tract pathogens and drug resistance genes through the use of Illumina’s Urinary Pathogen/Drug Resistance Gene Detection (UPIP) kit.
The UPIP kit is recognized for its broad coverage of pathogenic microorganisms, sensitive detection capabilities, ability to indicate drug resistance, and quantitative analysis. It is capable of detecting 174 different pathogenic microorganisms, including bacteria, fungi, viruses, and parasites, thereby providing a comprehensive diagnostic tool for urinary tract infections.- Flcube.com
